GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Net Change in Cash

HQL (abrdn Life Sciences Investors) Net Change in Cash : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

abrdn Life Sciences Investors's Net Change in Cash for the six months ended in Mar. 2025 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

abrdn Life Sciences Investors Net Change in Cash Historical Data

The historical data trend for abrdn Life Sciences Investors's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Net Change in Cash Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Net Change in Cash
Get a 7-Day Free Trial - - - - -

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

abrdn Life Sciences Investors Net Change in Cash Calculation

abrdn Life Sciences Investors's Net Change in Cash for the fiscal year that ended in Sep. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0+0+0+0
=0.00

abrdn Life Sciences Investors's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=8.415+0+-8.415+0
=0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

abrdn Life Sciences Investors Net Change in Cash Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

abrdn Life Sciences Investors Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Net Change in Cash
Comparable Companies
JRI PFL VKI HIO MVF LEO MYN SAR SOR EFR BLK KKR BX TSX:BN OSTO:INVE A TSX:BAM APO LSE:III AMP OSTO:EQT
Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
Website
https://www.abrdnhql.com
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
Executives
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
Kathleen Goetz director 1310 OAK VALLEY CIRCLE, POLK CITY IA 50226
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103